Skip to main content

A Study of BGB-11417 in Participants With Myeloid Malignancies

Recruiting · Phase 1, Phase 2 · NCT04771130

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm

At a glance

Research payments reported, 2025
$576,303
U.S. investigators named
5
Sites paid
8
Planned or actual enrollment
260

About the trial

Sponsor
BeOne Medicines
Tested
BGB-11417 (drug), Azacitidine (drug), Posaconazole (drug), BGB-11417 (drug), BGB-11417 (drug)
Dates
Started 2021-05-24; completion 2028-08-31
Results posted
Not yet

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

From ClinicalTrials.gov, last updated 2026-09-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines USA, Inc. reported $576,303 in research payments for this study in 2025 (90 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • The Medical College of Wisconsin, Inc. $232,027
  • UPMC Cancer Centers $176,989
  • The Medical College of Wisconsin $50,426
  • City of Hope National Medical Ctr $41,076
  • Ut MD Anderson Cancer Center $33,207
  • Tampa General Hospital, FL $26,163
  • Tampa General Hospital $8,207
  • Florida Cancer Specialists & Research Institute, LLC $8,207

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.